Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Receivables - Other: 2023-2024

Historic Receivables - Other for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $173,000.

  • Monte Rosa Therapeutics' Receivables - Other rose 734.45% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 734.45%. This contributed to the annual value of $173,000 for FY2024, which is 65.74% down from last year.
  • Monte Rosa Therapeutics' Receivables - Other amounted to $173,000 in FY2024, which was down 65.74% from $505,000 recorded in FY2023.
  • Over the past 5 years, Monte Rosa Therapeutics' Receivables - Other peaked at $505,000 during FY2023, and registered a low of $173,000 during FY2024.
  • Moreover, its 2-year median value for Receivables - Other was $339,000 (2023), whereas its average is $339,000.
  • Data for Monte Rosa Therapeutics' Receivables - Other shows a maximum YoY crashed of 65.74% (in 2024) over the last 5 years.
  • Over the past 2 years, Monte Rosa Therapeutics' Receivables - Other (Yearly) stood at $505,000 in 2023, then plummeted by 65.74% to $173,000 in 2024.